Académique Documents
Professionnel Documents
Culture Documents
June 2016
General economic and business conditions in India and other key global markets in which we operate;
The ability to successfully implement our strategy, our research and development efforts, growth & expansion plans and
technological changes;
Changes in the value of the Rupee and other currency changes;
Changes in the Indian and international interest rates;
Allocations of funds by the Governments in our key global markets;
Changes in laws and regulations that apply to our customers, suppliers, and the pharmaceutical industry;
Increasing competition in and the conditions of our customers, suppliers and the pharmaceutical industry; and
Changes in political conditions in India and in our key global markets.
Should one or more of such risks and uncertainties materialize, or should any underlying assumption prove incorrect, actual outcomes
may vary materially from those indicated in the applicable forward-looking statements.
For more detailed information on the risks and uncertainties associated with the Companys business activities, please see the
Companys Form 20-F for the fiscal year ended March 31, 2015, and Form 6-K for the quarters ended June 30, 2015, September 30,
2015, December 31, 2015 and its other filings with the Securities and Exchange Commission. Any forward-looking statement or
information contained in this presentation speaks only as of the date of the statement. We are not required to update any such
statement or information to either reflect events or circumstances that occur after the date the statement or information is made or to
account for unanticipated events
Contents
Update on US FDA matter
Executive Summary
Company Overview
Sustainable performance over the past 5 years
Optimistic future
FY17 Priorities
December
2015
Warning Letter
For Three Sites
Response Submitted
January 2016
First status update
Activity
Status
Document Control
Done
Nearly done
Infrastructure upgrades
Nearly done
WIP
Sterility assurance
Nearly done
Manufacturing procedures
WIP
Investigation rigor
WIP
March 2016
Second status update
May 2016
Third status update
Of the
Warning Letter
Commitments,
94% will be
completed by
June.
No questions or
comments by
FDA to date
Executive Summary
Top Line Growth with Healthy Profitability
Well-positioned
for sustained profitable
growth given our proven
capability in complex
generics with strategic
investments in R&D
for Proprietary Products
and Biologics
Recent
Highlights:
Proprietary
Products
Closed three
deals to
a assets
In-license
Xeglyze, XP23829
E 7777
Recent
Highlights:
North America
Generics
Acquisition
of 6 OTC
brands with
strong brand
equity
Recent
Highlights:
Emerging
Markets
Reditux
Approved in
Russia and
Venezuela!
Company
Overview
Partner of Choice
Global Generics
Proprietary Products
Access to affordable
medicines
11
Industry
leading
product
development
skills
Deep market
presence
Early mover
advantage
in Biosimilars
Vertically
integrated
organization
with modern
infrastructure
20 USFDA inspected
formulation & API
manufacturing facilities
12
CAPABILITIES
Oral Solids
(22 bn pills annual)
Tablets, Capsules,
Pellets, bi-layers,
Modified / Extended
release, ODTs
DETAILS
Injectable
(110 mn units annual)
Ointments
(10mn units annual)
13
Complex Injectable
Centre of Excellence
Leiden, Netherlands
UK
Complex
generics &
Proprietary
products
Princeton, NJ,
USA
Germany
Italy
Product
Development
Centres, Hyderabad
& Bangalore
Aurigene Discovery
Technologies Ltd,
Bangalore
External partners
14
Sustainable
performance
over
five years
Sustainable revenue
growth over last 5
years
+10%
14,819
15,471
FY15
FY16
13,217
11,627
9,674
FY12
FY13
FY14
EBITDA
45,000
10,000
GROSS MARGIN
9,228
8,540
9,000
28%
25%
24%
40,000
60%
7,580
8,000
26%
62%
5,331
26%
35,000
24%
58%
2,541
58%
57%
2,782
3,318
4,134
3,625
3,617
30,000
6,000
26.6% **
23%
60%
6,058
7,000
24%
22%
25,000
20%
20,000
18%
15,000
16%
10,000
14%
5,000
12%
56%
5,000
54%
4,000
55%
52%
3,000
52%
2,000
50%
1,000
48%
-
FY12
FY13
FY14
Gross Margin
FY15
% to Sales
FY16
10%
FY12
FY13
EBITDA
FY14
FY15
Adj. EBITDA
FY16
% to Sales
RoCE
FREE CASH FLOWS
695
589
FY12
FY13
876
930
FY14
FY15
26.8%**
1,875
FY16
29.6%
28.3%
28.2%
FY12
FY13
FY14
ROCE
26.1%
22.4%
FY15
FY16
Adj. ROCE
Dr. Reddys Laboratories Ltd.
17
+15%
1,168
1,044
STRATEGIC FOCUS
921
671
738
FY13
FY14
FY15
FY16
Russia business
sustaining uncertain
macro economic
conditions
10,115
FY15
FY16
8,891
STRATEGIC FOCUS
8,041
6,817
FY12
FY13
FY14
+12%
2,129
1,787
STRATEGIC FOCUS
1,293
1,456
1,571
FY12
FY13
FY14
FY15
FY16
Despite modest
performance, PSAI
continues to be strategic
differentiator
417
STRATEGIC FOCUS
345
FY12
FY13
FY14
FY15
FY16
Optimistic
future
Purpose
We accelerate
access to affordable
medicines
because
Good
Health
Cant
Wait.
Our promises
Bringing expensive
medicine within
reach
First-to-market,
tough-to-make
products
Addressing unmet
patient needs
Differentiated
formulations
for unmet medical
needs
Helping patients
manage disease
better
Enabling and helping
our partners ensure
that our medicines
are available where
needed
Value-added services
for patients and
customers
Reliable & flexible
supply chain
23
Topical/
Transdermal,
6
Softgel, 5
OSD, 27
Complex
Inj/ Sterile,
17
Inj, 10
Complex
OSD, 17
24
3
2
1
Grafeel
Reditux
Cresp
Peg-grafeel
Dr. Reddys peg filgrastim
launched; End-to-end
development in-house
(single source
pegfilgrastim)
2014
2012
2011
2010
2007
Pre-2006
25
Product
Portfolio
FY20
Business
Profile
FY25
Business
Profile
26
Reverse
Translation-based
Product
Development
Engine
Promius Pharma: A
unique, unmet-need
driven Specialty
Dermatology and
Neurology company
Commercialization
Model focused on
solving patient
challenges [focusing
directly on both
physician and
patient]
27
Provide innovative
services around
our products
Value-added service
offerings
PROPRIETARY
PRODUCTS
API AND
GENERICS
BRANDED
GENERICS
28
FY17
Priorities
FY17 Priorities
Growth
Organization
Operations
Strengthen quality
management systems and
processes
30
Contacts
Investor relations
Media relations
Kedar Upadhye
Calvin Printer
kedaru@drreddys.Com
calvinprinter@drreddys.Com
(Ph: +91-40-66834297)
About Dr. Reddys: Dr. Reddys Laboratories Ltd. (NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its
three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products Dr. Reddys offers a portfolio of products and services including APIs, custom
pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastro-intestinal, cardiovascular, diabetology, oncology, pain management and
anti-infectives. Dr. Reddys operates in markets across the globe. Our major markets include USA, Russia & CIS, Venezuela and India. For more information, log on to: www.drreddys.com
.....
Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the managements current views and assumptions and involve
known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which
are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions
identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as
performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and
trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or
reorganisation , including related integration issues.
The company assumes no obligation to update any information contained herein.
Registered Office: Dr. Reddys Laboratories Ltd. 8-2-337 | Road No. 3, Banjara Hills, Hyderabad - 500034, Telangana, India.
Tel: 91 40 4900 2900 | Fax: 91 40 4900 2999 | Web: www.drreddys.com